{"id":3375,"date":"2026-06-01T06:53:22","date_gmt":"2026-06-01T13:53:22","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=3375"},"modified":"2026-06-01T06:56:30","modified_gmt":"2026-06-01T13:56:30","slug":"henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/","title":{"rendered":"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">May 26, 2026 \u2013 Henlius (2696.HK) announces that the first patient has been dosed in China in a randomized, double\u2011blind, multicenter, parallel\u2011controlled Phase II\/III clinical study of the company&#8217;s self\u2011developed recombinant anti\u2011EGFR monoclonal antibody pimurutamab (HLX07) in combination with anti\u2011PD\u20111 monoclonal antibody H drug Hetronifly\u00ae (serplulimab, European trade name: Hetronifly\u00ae) plus chemotherapy as first\u2011line treatment for patients with advanced squamous non\u2011small cell lung cancer (sqNSCLC). This milestone marks the official initiation of the study in China. Recently, the study also received Clinical Trial Notification (CTN) clearance in Australia, demonstrating steady global clinical progress.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pimurutamab is a self\u2011developed anti\u2011EGFR monoclonal antibody of Henlius that features lower immunogenicity and improved EGFR target affinity. Through Fc engineering, the antibody also achieves a significantly extended half\u2011life, and its once\u2011every\u2011three\u2011week dosing schedule makes it more suitable for clinical combination with immuno\u2011oncology products. Preclinical studies show that pimurutamab exhibits superior biological activity compared with similar anti\u2011EGFR antibodies, potently inhibits tumor cell growth in various tumor models, and shows strong synergy with H drug. The combination simultaneously blocks EGFR growth signals and activates immune responses, offering great synergistic therapeutic potential.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Based on this non\u2011clinical and clinical foundation, the Phase II\/III study (HLX07\u2011sqNSCLC301) will further systematically evaluate the clinical value of the pimurutamab + serplulimab + chemotherapy regimen as a first\u2011line treatment for patients with advanced sqNSCLC. The study aims to determine whether the synergy between EGFR targeting and immune pathways can overcome the efficacy bottleneck of current first\u2011line therapies and provide patients with a promising new treatment option. The study adopts an international multicenter design and is advancing concurrently in China and overseas markets<\/p>\n","protected":false},"excerpt":{"rendered":"<p>May 26, 2026 \u2013 Henlius (2696.HK) announces that the first patient has been dosed in China in a randomized, double\u2011blind, multicenter, parallel\u2011controlled Phase II\/III clinical study of the company&#8217;s self\u2011developed recombinant anti\u2011EGFR monoclonal antibody pimurutamab (HLX07) in combination with anti\u2011PD\u20111 monoclonal antibody H drug Hetronifly\u00ae (serplulimab, European trade name: Hetronifly\u00ae) plus chemotherapy as first\u2011line treatment [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":3376,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[],"class_list":["post-3375","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-development"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae - Xpharma China<\/title>\n<meta name=\"description\" content=\"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T13:53:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T13:56:30+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/Henlius.png\" \/>\n\t<meta property=\"og:image:width\" content=\"420\" \/>\n\t<meta property=\"og:image:height\" content=\"310\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Research news\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Research news\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/\"},\"author\":{\"name\":\"Research news\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/60aeb68e89c44ad7a4681a609e570a06\"},\"headline\":\"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae\",\"datePublished\":\"2026-06-01T13:53:22+00:00\",\"dateModified\":\"2026-06-01T13:56:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Henlius.png\",\"articleSection\":[\"Drug development\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/\",\"name\":\"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Henlius.png\",\"datePublished\":\"2026-06-01T13:53:22+00:00\",\"dateModified\":\"2026-06-01T13:56:30+00:00\",\"description\":\"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Henlius.png\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Henlius.png\",\"width\":420,\"height\":310},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-development\\\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/60aeb68e89c44ad7a4681a609e570a06\",\"name\":\"Research news\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68f7ef69a25039b992927cbac363f20eca8c5bb89e11502c988f6c265875ad7e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68f7ef69a25039b992927cbac363f20eca8c5bb89e11502c988f6c265875ad7e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68f7ef69a25039b992927cbac363f20eca8c5bb89e11502c988f6c265875ad7e?s=96&d=mm&r=g\",\"caption\":\"Research news\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/research-news\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae - Xpharma China","description":"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/","og_locale":"en_US","og_type":"article","og_title":"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae - Xpharma China","og_description":"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-06-01T13:53:22+00:00","article_modified_time":"2026-06-01T13:56:30+00:00","og_image":[{"width":420,"height":310,"url":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/Henlius.png","type":"image\/png"}],"author":"Research news","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"Research news","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/"},"author":{"name":"Research news","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/60aeb68e89c44ad7a4681a609e570a06"},"headline":"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae","datePublished":"2026-06-01T13:53:22+00:00","dateModified":"2026-06-01T13:56:30+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/Henlius.png","articleSection":["Drug development"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/","url":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/","name":"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/Henlius.png","datePublished":"2026-06-01T13:53:22+00:00","dateModified":"2026-06-01T13:56:30+00:00","description":"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/Henlius.png","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/Henlius.png","width":420,"height":310},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/drug-development\/henlius-first-patient-dosed-in-china-in-international-multicenter-study-of-pimurutamab-hlx07-combined-with-h-drug-hetronifly\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Henlius: First patient dosed in China in international multicenter study of pimurutamab (HLX07) combined with H drug Hetronifly\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/60aeb68e89c44ad7a4681a609e570a06","name":"Research news","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/68f7ef69a25039b992927cbac363f20eca8c5bb89e11502c988f6c265875ad7e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/68f7ef69a25039b992927cbac363f20eca8c5bb89e11502c988f6c265875ad7e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68f7ef69a25039b992927cbac363f20eca8c5bb89e11502c988f6c265875ad7e?s=96&d=mm&r=g","caption":"Research news"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/research-news\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=3375"}],"version-history":[{"count":2,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3375\/revisions"}],"predecessor-version":[{"id":3378,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3375\/revisions\/3378"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media\/3376"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=3375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=3375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=3375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}